Clinical trials: Cancer and / or Hematological Malignancy, open to volunteers
- Condition Cancer and / or Hematological Malignancy
- Status Open to volunteers
- Age group Children (under 18)
Inherited Hematological Diseases, Rare Diseases
Longitudinal Studies of Patient With FPDMM
Background: Genes tell the body and its cells how to work. Familial platelet disease (FPD) or FPD with associated malignancies (FPDMM) is caused by a variant in the gene RUNX1.
- Conditions
- Inherited Hematological Diseases, Rare Diseases, FPDMM
- Trial name
- NCT03854318
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Solid and Hematological Malignancies, Autoimmune Diseases
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, anitocabtagene…
- Trial name
- NCT05041309
- Testing
- Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, Anitocabtagene autleucel
- Where
- 91 sites in United States, Australia and 12 more
- Volunteers
- 1,500 people
- Sponsor
- Kite, A Gilead Company
Oral Mucositis, Total Body Irradiation
Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant
The goal of this phase II, single-arm interventional clinical trial is to evaluate whether oral sodium copper chlorophyllin (CHL) can reduce the frequency and severity of oral mucositis in patients aged 12-65 years undergoing…
- Conditions
- Oral Mucositis, Total Body Irradiation, Hematological Malignancies, Hematopoietic Stem Cell Transplantation (HSCT)
- Trial name
- ChROMME-TBI (NCT07709195)
- Testing
- Sodium Copper Chlorophyllin
- Where
- India
- Volunteers
- 17 people
- Sponsor
- Tata Memorial Centre
Hematological Malignancy, GVHD - Graft-Versus-Host Disease
Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease.
Study Design Prospective, single center, single arm, Phase II study. Research aims and objectives Aim: To evaluate the efficacy and safety of standardized Withaferin A in steroid refractory acute GvHD in patients post allogeneic…
- Conditions
- Hematological Malignancy, GVHD - Graft-Versus-Host Disease, Steriod Refractory
- Trial name
- Withaferin_A (NCT07708987)
- Testing
- Standardized Withaferin A (SWA)
- Where
- India
- Volunteers
- 34 people
- Sponsor
- Tata Memorial Centre
Relapsed and Refractory CD5 Hematological Tumors
CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors
This is an investigator-initiated dose-finding clinical study with the primary objective of evaluating the safety of CD5CART in the treatment of subjects with relapsed and refractory CD5 hematological malignancies and to explore…
- Trial name
- NCT07234110
- Testing
- Fully human CD5 chimeric antigen receptor T cell injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Solid Tumors, Hematological Tumor
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
The goal of this clinical trial is to evaluate the efficacy and safety of romiplostim N01 in treating chemotherapy-induced thrombocytopenia (CIT) in children and adolescents/young adults (CAYA; aged 6-24 years) with hematologic…
- Conditions
- Solid Tumors, Hematological Tumor, Children, Adolescent
- Trial name
- NCT07043894
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Relapsed or Refractory EBV-associated Hematological Malignancies
A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
The main purpse of this study is to evaluate the safety and tolerability of KSD-101 in the treatment of relapsed or refractory EBV-associated hematological malignancies,to preliminarily explore the clinical efficacy ,evaluate the…
- Trial name
- NCT07532746
- Testing
- KSD-101
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Kousai Bio Co., Ltd.
Solid Tumor, Hematological Malignancies
Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology
This study aims to develop and implement a pediatric palliative care (PPC) program. It is an open-label, randomized trial (2:1 randomization) in pediatric oncology department of Children's Hospital of Fudan University.
- Trial name
- NiCE (NCT05306509)
- Testing
- NiCE, Routine PPC
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Children's Hospital of Fudan University
Lymphoma, Lymphoid Hematological Malignancies
Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
The INTeRCePT 2 study aims to develop a predictive assay to determine which patients with B cell lymphoma are most likely to respond to CAR T cell therapy.
- Trial name
- NCT07472972
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Acute Leukemia, Immune Deficiency Disorder
Umbilical Cord Blood Transplantation From Unrelated Donors
This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated…
- Conditions
- Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder
- Trial name
- NCT03016806
- Testing
- Total Body Irradiation 1200 cGy, Total Body Irradiation 200 cGy, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Pain Management, Anxiety
Distraction With Virtual Reality From Pain and Anxiety for Patients With Hematological Malignancies
The goal of this clinical trial] is to study the effectiveness of Virtual Reality (VR) in reducing pain and anxiety during painful procedures for patients with hematological malignancies The main question[s] it aims to answer…
- Conditions
- Pain Management, Anxiety, Procedures, Hematological Neoplasms
- Trial name
- NCT07085065
- Testing
- VR session
- Where
- Tunisia
- Volunteers
- 365 people
- Sponsor
- Yesmine Amara
Hematological Malignancies
National Longitudinal Cohort of Hematological Diseases (NICHE) - CART
This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies.
- Trial name
- NCT06607289
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematological Neoplasms
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.
- Trial name
- NCT03844360
- Testing
- Bortezomib, Eltrombopag, Imatinib
- Where
- 2 sites in China
- Volunteers
- 1,500 people
- Sponsor
- Wei Zhao
Malignant Hematological Diseases
A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases
Each year, over 20,000 patients in China undergo hematopoietic stem cell transplantation (HSCT). Unfortunately, the prognosis in patients with disease relapse or graft failure is often inferior.
- Trial name
- NCT06548958
- Testing
- Second Stem Cell Transplantation (SCT2)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Hematological Malignancies
Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies
This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using…
- Trial name
- DRP_ZH (NCT06550102)
- Where
- Switzerland
- Volunteers
- 1,000 people
- Sponsor
- University Children's Hospital, Zurich
Hematological Toxicity, Targeted Therapy
Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer
This multicenter, real-world, observational study will retrospectively and prospectively collect real-world data related to the investigational drugs.
- Conditions
- Hematological Toxicity, Targeted Therapy, Breast Cancer
- Trial name
- NCT06503380
- Testing
- No intervenrion.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Fudan University
Hematological Malignancies
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell…
- Trial name
- NCT04959903
- Testing
- Allogeneic T cell progenitors, cultured ex-vivo
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Smart Immune SAS
Hematological Malignancies
Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies
Clinical study on the safety and effectiveness of NK cells/combined monoclonal antibodies in the treatment of hematological malignancies
- Trial name
- NCT04662788
- Testing
- NK cells/Combined Monoclonal Antibodies
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhejiang University
Infectious Diseases, Hematological Malignancies
LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
A study of LMP1 CAR-T for patients with LMP1 positive infectious diseases and hematological malignancies
- Trial name
- NCT04657965
- Testing
- LMP1 CAR T-cells
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Zhejiang University
Relapsed and Refractory, Lymphoid Hematological Malignancies
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.
- Trial name
- NCT04283006
- Testing
- CD20/CD22 dual Targeted CAR T-cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- He Huang